RELAXIN: A MAGICAL THERAPY FOR HEALTHY HEART
Keywords:Relaxin, Relaxin family peptide receptor 1, Serelaxin, Heart failure
Relaxin (a peptide hormone) has emerged as a cardioprotective agent and plays a vital role in normal cardiac function. By activation a complex network of signaling cascade, relaxin is responsible for creating a healthy environment for heart functioning. Under pathological conditions, such as cardiomyopathy and heart failure, expression level of relaxin is increased dramatically to protect heart. By promoting angiogenesis, vasodilatation, improving ischemia/reperfusion injury and remodeling, relaxin has emerged as a magical agent to address cardiac abnormalities. Over the past 3 decades, various cardioprotection strategies are in use to deal with cardiac diseases, however till date no effective therapy is in clinical practice. Relaxin has emerged as a novel therapeutic agent to have beneficial action during various pathological conditions. In this review, we have discussed different cardioprotective roles of relaxin that marks it, as an effective agent to tackle heart related diseases.Â
F Hisaw. Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med 1926;23:661-3.
CD Sherwood, EM O'Byrne. Purification and characterization of porcine relaxin. Arch Biochem Biophysics 1974;160:185-96.
HM Bathgate RA, Van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev 2013;93:405-80.
RAD Bathgate, Hsueh AJW, Sherwood OD. Physiology and molecular biology of the relaxin peptide family. In: JD Neill. Ed. Knobil and Neill's Physiology of Reproduction. 3rd edition; 2006b. p. 679âˆ’768.
SY Hsu. New insights into the evolution of the relaxin-LGR signaling system. Trends Endocrinol Metab 2003;14:303-9.
BC Dschietzig T, Richter C. Relaxin, a pregnancy hormone is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappa B. Circ Res 2003;92:32-40.
Q Zhang, SH Liu, M Erikson, M Lewis, E Unemori. Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J Cell Biochem 2002;85:536-44.
ML Halls, RA Bathgate, RJ Summers. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol Pharmacol 2006;70:214-26.
WP Shaw EE, Kulpa J. Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am J Physiol Heart Circ Physiol 2009;297:H29-H36.
DG Ward, GR Thomas, MJ Cronin. Relaxin increases rat heart rate by a direct action on the cardiac atrium. Biochem Biophys Res Commun 1992;186:999-1005.
H Kakouris, LW Eddie, RJ Summers. Cardiac effects of relaxin in rats. Lancet 1992;339:1076-8.
X Han, Y Habuchi, WR Giles. Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells. Circulation Res 1994;74:537-41.
YY Tan, Wade JD, Tregear GW, Summers RJ. Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues. Br J Pharmacol 1998;123:762-70.
T Bani-Sacchi, M Bigazzi, D Bani, PF Mannaioni, E Masini. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995;116:1589-94.
GR Thomas, R Vandlen. The purely chronotropic effects of relaxin in the rat isolated heart. J Pharm Pharmacol 1993;45:927-8.
M Toth, P Taskinen, H Ruskoaho. Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J Endocrinol 1996;150:487-95.
CS Samuel, EN Unemori, I Mookerjee, RA Bathgate, SL Layfield, J Mak, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145:4125-33.
ED Lekgabe, H Kiriazis, C Zhao, Q Xu, XL Moore, Y Su, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005;46:412-8.
RC Dschietzig T, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001;15:2187-95.
E Masini, D Bani, MG Bello, M Bigazzi, PF Mannaioni, TB Sacchi. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 1997;138:4713-20.
D Bani, E Masini, MG Bello, M Bigazzi, TB Sacchi. Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 1998;152:1367-76.
E Masini, G Zagli, JF Ndisang, M Solazzo, PF Mannaioni, D Bani. Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway. Br J Pharmacol 2002;137:337-44.
JR Teerlink, G Cotter, BA Davison, GM Felker, G Filippatos, BH Greenberg, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.